title: Migraine headache prophylaxis in adolescents.
abstract: Migraine headache is estimated to affect up to 28 percent of adolescents, most of whom are female. Chronic migraine in this population has been associated with reduced quality of life and academic disruption due to missed school days. Historically, migraine headache was treated episodically as it occurred. In March 2014 the U.S. Food and Drug Administration approved an existing medication, topiramate (Topamax®), for migraine prophylaxis in adolescents between the ages of 12 and 17. This is the first FDA approval of a drug for migraine prevention in this population. There are several possible adverse effects of taking topiramate, some potentially serious, so adequate education for adolescents and their families on all the potential benefits and risks is imperative.
authors.forename: Heidi Collins
authors.initials: HC
authors.lastname: Fantasia
mesh_terms: D000293:Adolescent; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D000077236:Topiramate; D014481:United States; D055815:Young Adult
chemical_list: D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose
keywords: Topamax; adolescents; headache; migraine prevention; topiramate